• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验申请中的逐步把关程序。

Stepwise gatekeeping procedures in clinical trial applications.

作者信息

Dmitrienko Alex, Tamhane Ajit C, Wang Xin, Chen Xun

机构信息

Eli Lilly and Company, Indianapolis, IN 46285, USA.

出版信息

Biom J. 2006 Dec;48(6):984-91. doi: 10.1002/bimj.200610274.

DOI:10.1002/bimj.200610274
PMID:17240656
Abstract

This paper discusses multiple testing problems in which families of null hypotheses are tested in a sequential manner and each family serves as a gatekeeper for the subsequent families. Gatekeeping testing strategies of this type arise frequently in clinical trials with multiple objectives, e.g., multiple endpoints and/or multiple dose-control comparisons. It is demonstrated in this paper that the parallel gatekeeping procedure of Dmitrienko, Offen and Westfall (2003) admits a simple stepwise representation (n null hypotheses can be tested in n steps rather than 2n steps required in the closed procedure). The stepwise representation considerably simplifies the implementation of gatekeeping procedures in practice and provides an important insight into the nature of gatekeeping inferences. The derived stepwise gatekeeping procedure is illustrated using clinical trial examples.

摘要

本文讨论了多重检验问题,其中原假设族以序贯方式进行检验,且每个原假设族作为后续原假设族的把关者。这种类型的把关检验策略在具有多个目标的临床试验中经常出现,例如多个终点和/或多个剂量-对照比较。本文证明,德米特里延科、奥芬和韦斯特福尔(2003年)提出的平行把关程序具有一种简单的逐步表示形式(n个原假设可以分n步进行检验,而不是封闭式程序所需的2n步)。这种逐步表示形式在实践中极大地简化了把关程序的实施,并为把关推断的本质提供了重要的见解。文中使用临床试验示例对推导得出的逐步把关程序进行了说明。

相似文献

1
Stepwise gatekeeping procedures in clinical trial applications.临床试验申请中的逐步把关程序。
Biom J. 2006 Dec;48(6):984-91. doi: 10.1002/bimj.200610274.
2
A cautionary note on design implications when the primary analysis is a stratified analysis of a binary endpoint.当主要分析是对二元终点进行分层分析时,关于设计影响的警示说明。
Biom J. 2006 Dec;48(6):978-83. doi: 10.1002/bimj.200610291.
3
Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypotheses.用于具有多个假设序列的多重性问题的基于混合的把关程序。
J Biopharm Stat. 2016;26(4):758-80. doi: 10.1080/10543406.2015.1074917. Epub 2015 Aug 6.
4
Multistage and mixture parallel gatekeeping procedures in clinical trials.临床试验中的多阶段和混合平行把关程序。
J Biopharm Stat. 2011 Jul;21(4):726-47. doi: 10.1080/10543406.2011.551333.
5
A goodness-of-fit test for the marginal Cox model for correlated interval-censored failure time data.对相关区间删失失效时间数据的边际Cox模型进行拟合优度检验。
Biom J. 2006 Dec;48(6):1020-8. doi: 10.1002/bimj.200510269.
6
The analysis of stratified 2 x 2 contingency tables.分层2×2列联表的分析
Biom J. 2006 Dec;48(6):992-1007. doi: 10.1002/bimj.200610277.
7
Non-inferiority testing with a variable margin.采用可变界值的非劣效性检验。
Biom J. 2006 Dec;48(6):948-65. doi: 10.1002/bimj.200610271.
8
On testing simultaneously non-inferiority in two multiple primary endpoints and superiority in at least one of them.关于同时检验两个多个主要终点的非劣效性以及其中至少一个终点的优效性。
Biom J. 2006 Dec;48(6):916-33. doi: 10.1002/bimj.200510289.
9
Three methods for constructing parallel gatekeeping procedures in clinical trials.在临床试验中构建平行把关程序的三种方法。
J Biopharm Stat. 2011 Jul;21(4):768-86. doi: 10.1080/10543406.2011.554130.
10
A Dunnett-Bonferroni-based parallel gatekeeping procedure for dose-response clinical trials with multiple endpoints.一种基于邓尼特-邦费罗尼法的用于多终点剂量反应临床试验的平行把关程序。
Pharm Stat. 2009 Oct-Dec;8(4):301-16. doi: 10.1002/pst.358.

引用本文的文献

1
Recent innovations in adaptive trial designs: A review of design opportunities in translational research.适应性试验设计的最新创新:转化研究中的设计机会综述。
J Clin Transl Sci. 2023 Apr 28;7(1):e125. doi: 10.1017/cts.2023.537. eCollection 2023.
2
Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study.随机评估房颤决策支持干预措施的研究:RED-AF 研究的原理和设计。
Am Heart J. 2022 Jun;248:42-52. doi: 10.1016/j.ahj.2022.02.010. Epub 2022 Feb 24.
3
The minimum intensity of a mixed exposure that increases the risk of an outcome.
增加某种结果风险的混合暴露的最小强度。
Stat Med. 2020 Nov 30;39(27):4016-4024. doi: 10.1002/sim.8705. Epub 2020 Sep 3.
4
In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial.心力衰竭住院期间睡眠呼吸暂停的院内管理:一项随机对照试验。
J Card Fail. 2020 Aug;26(8):705-712. doi: 10.1016/j.cardfail.2020.06.007. Epub 2020 Jun 24.
5
Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).奥昔布宁与安慰剂治疗有或无乳腺癌女性潮热的随机双盲临床试验(ACCRU SC - 1603)
JNCI Cancer Spectr. 2019 Oct 21;4(1):pkz088. doi: 10.1093/jncics/pkz088. eCollection 2020 Feb.
6
Family Access to a Dentist Study (FADS): A multi-center randomized controlled trial.家庭获得牙医服务研究(FADS):一项多中心随机对照试验。
Contemp Clin Trials. 2015 Nov;45(Pt B):177-183. doi: 10.1016/j.cct.2015.10.006. Epub 2015 Oct 20.
7
Platelet count mediates the contribution of a genetic variant in LRRC16A to ARDS risk.血小板计数介导了LRRC16A基因变异对急性呼吸窘迫综合征风险的影响。
Chest. 2015 Mar;147(3):607-617. doi: 10.1378/chest.14-1246.